Vincristine liposomal (Marqibo) for relapsed or refractory acute lymphoblastic leukaemia â“ third line

Source:
Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA
Publisher:
Centre for Reviews and Dissemination
Publication date:
04 March 2016

Abstract

This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA databaseXAO: Acute lymphoblastic leukaemia is a cancer of the blood. It causes the bone marrow to make large numbers of abnormal white blood cells, which means the bone marrow is less able to make normal red blood cells, white blood cells, and platelets. Treatments for acute lymphoblastic leukaemia are often successful at first, especially in children, but the disease often returns and is much more difficult to treat in adults. Vincristine liposomal is a new form of a chemotherapy drug called vincristine that may be more effective and less toxic than current chemotherapy because it is encapsulated in a protective shell. It is delivered straight into the bloodstream via a drip. Some studies have suggested vincristine liposomal may be helpful for people whose first two treatments have already failed and the leukaemia has returned. It is now being studied to see how well it works and whether it is safe for patients to use. If vincristine liposomal is licenced for use in the UK, it could be a new treatment option for patients with acute lymphoblastic leukaemia that may improve survival when two current treatments have already stopped working. It may also cause fewer side effects than the current form of vincristine